Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Utah Medical Products, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Shareholders tender approximately 1.3 mil. shares under an $8-per-share repurchase offer announced May 26 (1"The Gray Sheet" May 31, p. 20). UM will purchase about 1.15 mil. of the shares "in accordance with the applicable regulations of the SEC, which allow the company to purchase pursuant to the offer an additional amount of shares not to exceed 2% of UM's outstanding shares," the firm explains. About 6.5 mil. shares will be outstanding after the repurchase. "Shareholders who did not tender their shares now own 18% more of UM than they did before the offer expired" July 23, the Salt Lake City firm says

You may also be interested in...

Utah Medical Products, Inc.

Plans to repurchase at least 800,000 shares at $8 each "if tendered and not withdrawn by shareholders on or before July 9," the firm states. The $8 figure is equal to the highest trading price over the last 12 months. The repurchase plan reflects management's feeling that the stock is currently undervalued relative to the firm's prospects

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects

Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA  neuroscientist Andrew Shen.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts